SciSparc has begun recruiting children with autism spectrum disorder in the trial of SCI-210 in Israel. Credit: Gatot Adri / Shutterstock.

Israeli pharmaceutical company SciSparc has begun recruiting subjects in a clinical trial of SCI-210 for treating children with autism spectrum disorder (ASD).

The company has been recruiting paediatric patients with ASD at Soroka Medical Center in Beersheba, Israel.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

SCI-210 is a combination of cannabidiol (CBD) and CannAmide that is intended to relieve symptoms of ASD.

The randomised, double-blind and placebo-controlled trial will enrol 60 participants aged five to 18 years over a period of 20 weeks.

The study aims to compare the effects of SCI-210 with those of standard CBD treatment in managing ASD symptoms.

Its primary efficacy metrics include the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire, the Clinical Global Impressions-Improvement (CGI-I) scale, and the determination of an effective therapeutic dose.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

SciSparc designed the trial in partnership with Israel’s National Autism Research Center.

The company initially aims to introduce SCI-210 domestically in Israel, followed by launches in other countries subject to regulatory approvals.

ASD is a neurodevelopmental disorder that affects a person’s social interaction and communication skills, with a range of symptoms and severities.

SciSparc CEO Oz Adler said: “The initiation of patient recruitment for this clinical study, which has the potential to address an area of unmet medical need, marks an exciting milestone for the team at SciSparc as it aligns with our mission to improve human health through the development of novel therapies.

“We hope the outcome of the trial will enable the company to proceed with the commercialisation process for SCI-210 in Israel.”

Last year, SciSparc received approval for the trial from the Israeli Ministry of Health and the Soroka University Medical Center Ethics Committee.

Based in Tel Aviv, the company specialises in cannabinoid-based pharmaceutical technologies and assets.

Its other therapies in development include SCI-110 for Tourette syndrome, Alzheimer’s disease and agitation, as well as SCI-160 for pain management.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact